Skip to main content

Table 1 Patients’ characteristics and nutrient intake profiles

From: Transglucosidase improves the gut microbiota profile of type 2 diabetes mellitus patients: a randomized double-blind, placebo-controlled study

  Placebo (n = 20) TGD 300 mg/day (n = 20) TGD 900 mg/day (n = 20) p value
Characteristic
  Sex (male/female) 9/11 14/6 12/8 0.272
  Age (year) 61.8 ± 8.1 62.4 ± 10.3 62.7 ± 8.3 0.928
  Body mass index (kg/m2) 22.8 ± 4.2 25.1 ± 4.8 23.2 ± 3.1 0.187
  HbA1c (%) 6.9 ± 0.7 6.7 ± 0.5 6.7 ± 0.4 0.319
  Fasting blood glucose (mg/dL) 141.4 ± 35.3 143.8 ± 20.1 148.8 ± 23.7 0.677
  Insulin (mU/mL) 9.2 ± 8.1 13.7 ± 17.5 13.2 ± 21.9 0.651
Nutrients
  Energy (Kcal) 1565 ± 320 1768 ± 417 1671 ± 321 0.203
  Protein (g) 51.3 ± 11.1 56.9 ± 11.7 52.7 ± 8.4 0.203
  Fat (g) 39.8 ± 7.3 45.0 ± 10.3 39.3 ± 8.2 0.069
  Cholesterol (mg) 254 ± 80 234 ± 53 235 ± 64 0.548
Ongoing diabetes therapies, n (%)
  Insulin injection 3 (15) 2 (10) 6 (30) 0.235
  Metoformin 5 (25) 7 (35) 5 (25) 0.720
  Insulin secretagogue 13 (65) 12 (60) 9 (45) 0.414
  α-Glicosidase inhibitor 8 (40) 10 (50) 10 (50) 0.765
  PPAR-γ antagonist 5 (25) 5 (25) 5 (25) 1.000
  ≥2 diabetes drugs 11 (55) 11 (55) 9 (45) 0.766
  Lifestyle modification only 2 (4) 1 (5) 2 (4) 0.804
  1. TGD, transglucosidase; HbA1c, glycolated hemoglobin.